BioNTech falls after terminating colorectal cancer trial
BUZZ-BioNTech falls after terminating colorectal cancer trial ** U.S.-listed shares of German drugmaker BioNTech BNTX.O 22UAy.DE fall 8.6% to $101.84
** Shares of fellow mRNA drugmaker Moderna MRNA.O fall 5.2% to $135.37
** Co terminates mid-stage trial of its experimental personalized mRNA treatment autogene cevumeran in patients with high-risk colorectal cancer who had undergone surgery
** Says independent monitors found a numerical imbalance in overall survival between patients receiving the treatment and those under watchful waiting, and concluded that continuing the trial was unlikely to change the outcome
** Does not disclose which group had worse survival, but says no new safety concerns were found
** Says a separate trial testing the treatment with other cancer medicines in pancreatic cancer will continue as planned; treatment is being jointly developed with Roche's ROPC.S Genentech unit
** Including session's moves, BNTX up 7.9% YTD
(Reporting by Kunal Das in Bengaluru)
Recent news on Roche Holding AG
See all newsNovartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib
Brief: Roche Says Sefaxersen Achieved Statistically Significant 43.1% Reduction In Proteinuria In Interim Phase III Data
Brief: Zymeworks Signs Exclusive Global Licensing Deal With Roche For Cancer Drug ZW209
Zymeworks licenses experimental lung cancer drug to Roche in up to $813 million deal
DB ups Roche to 'buy' on positive oncology survey